Introduction
============

Off-label prescription of psychoactive drugs is emerging as a widespread phenomenon in many countries.[@b1-ndt-14-1125]--[@b4-ndt-14-1125] Whereas antipsychotic medications are indicated for the alleviation of psychotic symptoms of schizophrenia, mood disorders, and delirium, \~20% of all antipsychotic prescriptions in a US nationally representative survey were off-label.[@b4-ndt-14-1125] The most common off-label indications are for relief of insomnia, pain, and agitation.[@b5-ndt-14-1125],[@b6-ndt-14-1125] While effective antipsychotic medications are generally characterized as having antidopaminergic actions, there has been little information about the iatrogenic physiological and psychopathological perturbations provoked by off-label administration of antidopaminergic medication in patients without psychotic disorders.

Central dopaminergic transmission is the primary target of antipsychotic medications. Dopamine in turn acts as a key neurotransmitter in the brain, with a pronounced regulatory role for motor, limbic, motivational, and cognitive functions.[@b7-ndt-14-1125] Consequently, some recent investigations have emphasized a negative impact of antipsychotics on cognitive function in patients with schizophrenia,[@b8-ndt-14-1125]--[@b12-ndt-14-1125] contrary to some older reports of their small beneficial cognitive effects.[@b13-ndt-14-1125]--[@b15-ndt-14-1125]

While molecular imaging by positron-emission tomography gives a direct index of central dopaminergic pathways,[@b16-ndt-14-1125] measurements of biogenic amine metabolites in blood and urine have for more than 50 years served as a surrogate index of central neurotransmitter metabolism. The main metabolites of interest in such examinations have been the serotonin metabolite 5-hydroxyindoleacetic acid (5-HIAA), the central noradrenaline metabolite 3-methoxy-4-hydroxyphenylglycol (MHPG), the peripheral noradrenaline metabolite vanil-lylmandelic acid (VMA), and especially the dopamine metabolite homovanillic acid (HVA). The plasma concentration of the latter metabolite (pHVA) is considered to bear a particular relation with the turnover of brain dopamine in experimental animals and humans.[@b17-ndt-14-1125]--[@b21-ndt-14-1125] These studies have shown that 11%--35% pHVA originates from the brain, whereas the remainder is derived from catecholamine metabolism in sympathetic nerves and the adrenal gland. Formed from brain dopamine by the successive actions of catechol-*O*-methyltransferase and monoamine oxidase, interstitial HVA diffuses from the brain by a probenecid-sensitive process, enters the circulation, and ultimately passes into the urine.[@b16-ndt-14-1125]

The link between pHVA and central dopamine transmission has motivated a large body of clinical research, most of which has been conducted in patients with schizophrenia. The results have been somewhat incongruent,[@b22-ndt-14-1125]--[@b30-ndt-14-1125] no doubt reflecting the clinical heterogeneity of schizophrenia, duration of illness, the mixed origin of pHVA, and effects of previous pharmacological treatments. Overall, these findings indicate a considerable association between plasma-catecholamine metabolites, as an indirect indicator of brain dopamine activity, and acute and delayed clinical responses to antipsychotic treatment.

However, relatively little is known about the corresponding associations in healthy individuals, or indeed in patients receiving off-label antidopaminergic treatments. In one of the few such studies, a positive correlation between age and pHVA levels in healthy men and women was reported,[@b31-ndt-14-1125] consistent with findings of age-dependent increases in brain dopamine turnover to positron-emission tomography.[@b32-ndt-14-1125] Another plasma-metabolite study reported an inverse correlation between pHVA and history of childhood trauma in adults with personality disorder and healthy controls,[@b33-ndt-14-1125] concurring with results of a similar study of 5-HIAA and HVA in cerebrospinal fluid,[@b34-ndt-14-1125] which is more closely reflective of central neurotransmitter metabolism. Still others observed an acute reduction in pHVA in healthy individuals subjected to experimental stress.[@b35-ndt-14-1125]

Another physiological parameter with high sensitivity to treatment with antipsychotics is the hormone prolactin. Its release from lactotroph cells of the anterior pituitary gland is tightly regulated by tonic dopaminergic inhibition.[@b36-ndt-14-1125] Indeed, the hypothalamic tuberoinfundibular dopaminergic system is considered the most important regulator of prolactin secretion.[@b37-ndt-14-1125] Treatment with antipsychotic medication causes disinhibition of lactotrophs and is indeed the common cause of pharmacologically induced hyperprolactinemia.[@b38-ndt-14-1125] This adverse side effect has been well described for first-generation[@b39-ndt-14-1125] and second-generation antipsychotics.[@b40-ndt-14-1125] As such, prolactin responses provide another approach for assessing pharmacodynamic response to antipsychotic medications. Decreased plasma prolactin is a surrogate for brain dopamine receptor-agonist occupancy in Parkinson's disease patients[@b41-ndt-14-1125] and there is an association between prolactin increases and cognitive effects of haloperidol in healthy volunteers,[@b42-ndt-14-1125] but there are barely any other reports in the context of off-label medication with antipsychotics.

Given the paucity of information about cognitive and physiological effects of off-label use of antidopaminergics, we undertook to study the relationship between plasma (pHVA, p5-HIAA, pMHPG) and urine metabolites (uHVA, u5-HIAA, uVMA) and prolactin levels in relation to general psychopathological and subjective conditions, particularly related to perceived cognitive interferences in healthy volunteers treated for 7 days with low doses of three antidopaminergic medications with entirely different mechanism of action: reserpine, aripiprazole, and haloperidol. We hypothesized that iatrogenic psychopathological and subjective impairments in healthy volunteers would be proportional to the biochemically indicated antidopaminergic effect of each substance.

Methods
=======

Experimental procedures
-----------------------

This single-blind, randomized, placebo-controlled, parallel-group study was conducted at the Department of Psychiatry, Psychotherapy, and Psychosomatics of University Hospital RWTH Aachen, Aachen, Germany. The study was approved by the German Federal Institute for Drugs and Medical Devices (BfArM) and the ethics committee responsible from RWTH Aachen University, and was conducted in accordance with the ethical standards laid down in the Helsinki Declaration of 1975, as revised in 1983. All participants gave written informed consent after the study protocol had been explained to them in detail.

Subjects
--------

Healthy subjects aged 18--55 years were recruited through advertisement. Prior to inclusion, they were screened for psychiatric history using the Structured Clinical Interview for DSM-IV,[@b43-ndt-14-1125] and had a physical examination. Exclusion criteria comprised presence or history of mental disorders, use of psychotropic drugs, and nicotine abuse or dependence, as well as presence or history of any significant medical or neurological disorder (specifically hypotension, long QT syndrome, cardiac arrhythmia, regular use of drugs causing QT prolongation on electrocardiography, peptic ulcer, ulcerative colitis, paralytic ileus, galactose intolerance, lactase deficit, glucose--galactose malabsorption, epilepsy, and reduced renal or liver function). All subjects were required to have a negative urine-toxicology screening before participating in the study. Electrocardiography, electroencephalography, routine laboratory parameters, and physical and neurological examination had to be without pathological findings. Participants were instructed to abstain from alcohol and operation of a vehicle during their participation in the study part. They affirmed not taking part in concomitant clinical studies.

For female participants, a negative pregnancy test and secure contraception were required. Females without regular hormonal contraception could participate only when in the follicular phase of the menstrual cycle. Women using contraception were included in the period of stable intake of combined oral contraceptive pills or retention of a vaginal ring. A total of 72 volunteers (mean age 26.3±6.2 years) were included, of which 34 males (mean age 24.9±4, range 22--43 years) and 38 females (mean age 27.5±7.5, range 20--50 years). Participants were randomly assigned to treatment groups in a single-blind procedure (unaware which drug they receive) with control for matching of sex and demographics, as presented in [Table 1](#t1-ndt-14-1125){ref-type="table"}.

Antidopaminergic interventions
------------------------------

Participants were randomly assigned to one of four groups of 18 each, and received either placebo or one of the three antidopaminergic substances orally. Three antipsychotic substances with entirely different mechanisms of action were investigated: aripiprazole, haloperidol, and reserpine. To ensure tolerability, doses were raised gradually (aripiprazole, first day 5 mg, second day 10 mg, third--seventh day 15 mg; haloperidol, first day 1 mg, second day 2 mg, third--seventh day 3 mg; reserpine, first day 0.25 mg, second day 0.5 mg, third--seventh day 1 mg), thus obtaining doses in the range employed for psychosis.

Aripiprazole is a relatively new antipsychotic medication, characterized by its partial agonism at several G-protein-coupled receptors (especially dopamine D~2~, D~3~ and D~4~ and serotonin 5HT~1A~, 5HT~2C~, and 5HT~7~) and its antagonistic action at other receptors (especially 5HT~2A~, and 5HT~6~).[@b44-ndt-14-1125] Haloperidol is the prototypic first-generation butyrophenone antagonist of dopamine D~2~ and D~3~ receptors and negligible binding to other receptors, with the exception of α~1B~-adrenergic receptors.[@b45-ndt-14-1125] Reserpine, an alkaloid from *Rauwolfia serpentina*, was introduced into the Western pharmacopoeia in 1952[@b46-ndt-14-1125] for treatment of psychosis. Reserpine acts by blocking the vesicular monoamine transporter type 2 in biogenic monoamine neurons,[@b47-ndt-14-1125] ultimately causing depletion in intraneuronal dopamine stores.[@b48-ndt-14-1125] Placebo was administered to the control group as an inactive white tablet, with dose escalation mimicking the active medications. For randomization, we used a computer-generated random-number list prepared by an investigator with no clinical involvement in the trial. Medications and placebo were administered in the presence of the investigators.

Clinical assessment
-------------------

Expert ratings were based on established psychiatric rating scales and clinical interviews, while raters were blind to group affiliation. Depressive symptoms were measured using the Beck Depression Inventory (BDI)[@b49-ndt-14-1125] and the 21-item Hamilton Rating Scale for Depression (HRSD).[@b50-ndt-14-1125] General psychopathological symptoms were assessed using the Positive and Negative Symptoms Scale (PANSS).[@b51-ndt-14-1125] For more detailed examination of clinically objective cognitive and affective impairments, depressive and cognitive PANSS components according to the model of Lindenmayer et al[@b52-ndt-14-1125] were included in further analysis. All scales were administered prior to the first drug intake (day 0) and again 24 hours (±2 hours) after the last drug intake (day 8).

In order to record subjective assessment of different aspects of well-being, we applied the visual analogue scale (VAS), which is commonly used for simplified rating of subjective states in research and clinical settings.[@b53-ndt-14-1125] By convention, the VAS consists of a straight 100 mm horizontal line, with end points labeled as the extreme boundaries of the sensation, feeling, or response to be measured. As such, the VAS is scored by measuring the distance in millimeters from one end of the scale to the subject's pencil mark on the line. According to the standardized procedure, we asked participants to score the level of their ability to concentrate, motivation, fatigue, drive, and general well-being between "worst/lowest imaginable" and "highest/best I can imagine" on the straight 100 mm horizontal line. Scales were also rated on days 0 and 8.

Prolactin determination
-----------------------

Blood samples were taken from participants' cubital vein between 11 am and 1:30 pm before the first medication intake and again 24 (±2) hours after the last treatment. Prolactin concentration was measured as reported previously.[@b54-ndt-14-1125]

Monoamine metabolite quantification
-----------------------------------

Additional 9 mL venous blood samples were taken on day 1 just prior to first administration of medication and again on day 8 at 24 (±2 hours) after last drug intake. Subjects had been instructed to follow a diet with low tyramine content (eg, avoiding aged dairy products) beginning at least 5 days prior to the investigation. Blood was immediately centrifuged at 1,850 *g* for 10 minutes (Rotixa/RP; Hettich, Vlotho, Germany) and portions of plasma stored at -80°C until analysis, with blinding to origin. After addition of internal standard, the analytes were concentrated by solid-phase extraction (Biotage, Uppsala, Sweden). Quantification of HVA and 5-HIAA was obtained by isocratic reverse-phase high-performance liquid chromatography with an Inertsil ODS analytical column (250×4.6 mm; GL Sciences, Tokyo, Japan) with electrochemical detection (Decade; Antec Scientific, Zoeterwoude, the Netherlands) according to the method of Gupta and Whelton (1992).[@b113-ndt-14-1125] For quantification of MHPG we used a Hypersil ODS column (250×4.6 mm; GL Sciences) with electrochemical detection according to a modification method.[@b55-ndt-14-1125] Recovery was 74%--80%, with sensitivity of about 1 ng/mL for HVA, MHPH, and 5-HIAA. Intra- and interassay coefficients of variation were 7.1%/19.8% for HVA, 6.9%/18.1% for MHPG, and 6.0%/7.3% for 5-HIAA.

Urine samples (24-hour) were acquired from all participants before first medication and at day 8. Accumulated urine was collected in a canister (UriSet 24; Sarstedt, Nümbrecht, Germany) containing 9 mL 20% hydrochloric acid for stabilization (50 µL). Portions (20 mL) of urine were analyzed in the central laboratory of University Hospital RWTH Aachen for concentrations of uHVA, uVMA, and u5-HIAA using a commercial kit (ChromSystems, Munich, Germany) entailing a solid-phase extraction cleanup and high-performance liquid chromatography with electrochemical detection.[@b56-ndt-14-1125] Interassay coefficients were about 6% for all three analytes. Only results from participants who completed the protocol (7 days' intake of medication or placebo) were included in the final analyses.

Statistical analysis
--------------------

All statistical analyses were conducted using SPSS software (version 20). Normal distributions of the data were obtained after natural logarithmic transformations. The significance of changes and group differences in monoamine metabolite concentrations under the different treatment conditions were assessed by repeated-measures analysis of variance (ANOVA). Student's *t*-test was used for multiple pairwise comparisons, as described in the Results section. Correlations between physiological outcome parameters in the second session and psychopathological scores were explored. All tests were two-tailed. An *α*-level of \<0.05 was considered statistically significant. To accommodate multiple testing, we used *α*-adjustment for Bonferroni correction.

Results
=======

Completers, dropouts, and side effects
--------------------------------------

Seven (four males and three females, mean age 24±2 years) of 18 participants (39%) randomized to the haloperidol group withdrew from the study, due to unpleasant extrapyramidal symptoms. All antidopaminergic interventions caused significant psychopathological changes and cognitive impairments, as described in detail in our previous reports.[@b57-ndt-14-1125],[@b58-ndt-14-1125] For technical reasons, some data were missing, resulting in complete data sets across all measures in 62 of the 72 subjects.

Biogenic amine metabolites in plasma and urine
----------------------------------------------

Mean concentrations of the catecholamine metabolites and the indoleamine metabolite 5-HIAA measured in plasma (pHVA, pHIAA, pMHPG) and urine (uHVA, uHIAA, uVMA) at baseline and day 8 are summarized in [Table 2](#t2-ndt-14-1125){ref-type="table"}. Repeated-measures ANOVA showed a significant time × group interaction for uHVA (*F*~3,61~=3.82, *P*=0.014) and uVMA in 24-hour urine (*F*~3,61~=4.59, *P*=0.006) and for pMHPG (*F*~3,59~=5.95, *P*=0.001). After Bonferroni correction (adjusted *α*=0.008), only the results for pMHPG and uVMA remained statistically significant. There were no significant findings for 5-HIAA or HVA.

For the metabolites with a significant time × group interaction in the variance analysis, we applied a post hoc analysis, which only in the reserpine group showed a significant change in metabolite levels on day 8 relative to baseline: uHVA increased from 24.3±9.2 to 38.0±13.7 ng/day (*P*\<0.001), uVMA increased from 16.6±7.4 to 25.5±11.5 ng/day (*P*=0.006), and pMHPG increased from 4.1±2.1 to 6.3±2.9 ng/mL (*P*=0.001) ([Figure 1](#f1-ndt-14-1125){ref-type="fig"}).

Correlations among biogenic amine metabolites, general psychopathology, and different aspects of subjective self-assessment (VAS) after antidopaminergic intervention
---------------------------------------------------------------------------------------------------------------------------------------------------------------------

Potential interrelations among catecholamine-metabolite concentrations after subchronic antidopaminergic treatment with observed psychopathological effects (PANSS, HRSD) and different aspects of subjective self-assessment (BDI, VAS) were examined in the entire group of participants receiving an active substance. These data have been reported in detail previously.[@b57-ndt-14-1125] Significant correlations were found mainly for pHVA ([Table 3](#t3-ndt-14-1125){ref-type="table"}). After applying Bonferroni correction (adjusted significance level 0.003), pHVA remained significantly positively correlated with PANSS total score and PANSS cognitive component. Further, pHVA correlated significantly negatively with subjective assessment of ability to concentrate and subjective assessment of general well-being. The correlation with the HRSD score fell just short of significance. pHIAA showed a significant negative correlation with subjective assessments of ability to concentrate and with general well-being. In sum, higher day 8 pHVA levels were associated with higher PANSS scores (PANSS total, PANSS cognitive), higher HRSD scores, and lower self-assessment of well-being and ability to concentrate. The last two items also correlated negatively with pHIAA.

Differences in psychopathology and subjective assessment with respect to changes in plasma prolactin
----------------------------------------------------------------------------------------------------

In our initial analysis of these data, we noted a significant increase in prolactin after treatment with haloperidol and reserpine but not aripiprazole.[@b54-ndt-14-1125] In order to examine the association between this increase and the subjective and objective measures of psychopathology, the scores obtained were compared between two subgroups of active drug recipients stratified for high prolactin increase (\>50% from baseline, mean ± SD 236%±189%, n=35) and little or no prolactin increase (\<50% from baseline, mean ± SD, 15.5%±32.5%, n=19) ([Table 4](#t4-ndt-14-1125){ref-type="table"}). A one-way multivariate analysis of covariance (MANCOVA) was carried out using the subgroup affiliation as independent variable to examine the relationship between prolactin increase and PANSS, HRSD, BDI, and VAS for general well-being, subjective ability to concentrate, fatigue, motivation, and drive as dependent variables and with sex as a covariate. The MANCOVA revealed a significant effect of subgroup affiliation (Pillai's trace *V*=0.357, *F*~10,42~=2.34; *P*=0.027). After Bonferroni correc tion (adjusted significance level 0.005), separate univariate ANOVAs remained significant for the outcome variables PANSS (*F*~1,51~=14.45, *P*\<0.001), PANSS depressive component (*F*~1,51~=13.1, *P*=0.001). VAS drive (*F*~1,51~=10.1, *P*=0.003). BDI (*F*~1,51~=7.4, *P*=0.009) and VAS ability to concentrate (*F*~1,51~=7.5, *P*=0.008) were nearly significant ([Figure 2](#f2-ndt-14-1125){ref-type="fig"}).

In one additional exploratory analysis, we examined whether change in prolactin level was indicative of medication tolerability ([Table 5](#t5-ndt-14-1125){ref-type="table"}). Within the haloperidol group, dropouts (subjects who terminated participation ahead of schedule due to intolerable side effects) showed a significantly higher increase in prolactin levels than subjects who completed the entire study protocol (361±99 vs 278±155, Mann--Whitney *U* test *P*=0.015).

Discussion
==========

In this single-blind, randomized, placebo-controlled study, 72 healthy participants received either an antidopaminergic substance or placebo for 7 days. We tested for interdependence between psychopathological and physiological effects of subchronic antidopaminergic treatments at doses typical of those employed in off-label applications (but less than in treatment of psychosis). Only the challenge with reserpine significantly altered catecholamine metabolites, ie, increased pMHPG and 24-hour uHVA and uVMA. This is in line with previous findings in animals treated with reserpine alkaloids,[@b59-ndt-14-1125] and is consistent with peripheral and central depletion of catecholamines, despite the low reserpine dose. Increased metabolism follows degranulation of synaptic vesicles, which exposes intracellular dopamine and norepinephrine pools to rapid metabolism by monoamine oxidase. Consecutively, partial depletion of brain dopamine resulted in impaired subjective state, psychopathological conspicuities, and diminished cognitive performance.

The lack of effects of subchronic haloperidol or aripiprazole treatment on plasma- or urine-metabolite concentrations was somewhat unexpected, considering the established acute effects of these compounds on dopamine turnover in the brain, manifesting in increased metabolite levels in brain, cerebrospinal fluid, and urine,[@b60-ndt-14-1125]--[@b62-ndt-14-1125] although some contrary results have also been reported.[@b63-ndt-14-1125] Interestingly, several studies have shown that the clinical response to antipsychotic medication (ie, a decrease in psychosis-rating scores) in schizophrenia parallels a decrease in pHVA over time.[@b64-ndt-14-1125]--[@b71-ndt-14-1125] This phenomenon has been linked to the concept of delayed depolarization block, in which therapeutic response follows a partial inactivation of brain dopamine neurons.[@b72-ndt-14-1125] Conversely, some studies have revealed an initial increase in pHVA during the first week of antipsychotic drug treatment paralleling an acute decrease in psychotic symptoms,[@b23-ndt-14-1125],[@b66-ndt-14-1125],[@b73-ndt-14-1125] which seems consistent with an acute stimulation of dopamine synthesis due to autoreceptor blockade. Further, decreasing pHVA levels have also been reported as an attribute of responder stats to treatment with antipsychotics.[@b74-ndt-14-1125]--[@b77-ndt-14-1125]

Opposite to these findings observed in patients with schizophrenia, in our study the 7-day treatment with haloperidol and aripiprazole did not induce a detectable change in pHVA concentration in healthy volunteers. Keeping in mind that less than a third of pHVA is likely derived from the brain, one possible explanation may be that the effects of the low doses of haloperidol and aripiprazole on plasma-metabolite levels may have been too low to be registered.

Further, seven of 20 subjects in our haloperidol group withdrew from the study due to adverse experiences; this reduced the statistical power of our haloperidol arm, but may also have introduced bias, in that (by excluding these seven from consideration) we inadvertently selected for individuals with lesser sensitivity to haloperidol. We have previously seen that haloperidol challenge can have a range of effects on human cognition in healthy volunteers, with three of nine subjects experiencing improvement in some cognitive domains after treatment for 3 days with haloperidol.[@b78-ndt-14-1125] Therefore, haloperidol at the present dose regimen may have unmasked a subgroup of seven healthy individuals with higher-than-average responsiveness. However, we detected no distinctive features in this small subgroup concerning their demographic characteristics or monoamine metabolite levels at baseline. Interestingly, they did show significantly greater acute stimulation of prolactin release than subjects who tolerated the haloperidol intake for the whole scheduled period of 7 days.

Present neutral findings with aripiprazole are particularly interesting with regard to the distinct mechanism of action of aripiprazole via partial dopamine-receptor agonism and functional selectivity.[@b79-ndt-14-1125],[@b80-ndt-14-1125] In cerebral microdialysis studies, acute aripiprazole strongly increased interstitial dopamine metabolites, while reducing 5-HIAA levels in rat prefrontal cortex and striatum. In contrast, chronic administration of aripiprazole produced "stabilization", with less pronounced effects in interstitial metabolites of dopamine and serotonin, consistent with present findings in healthy humans with subchronic treatment. Furthermore, aripiprazole may have net agonist effects at presynaptic D~2/3~ autoreceptors, with net antagonism at postsynaptic receptors,[@b81-ndt-14-1125] which would likely cause a dissociation between behavioral/cognitive effects and altered dopamine turnover.[@b82-ndt-14-1125],[@b83-ndt-14-1125] This proposition is in line with the relatively good tolerability and fewer side effects observed in the group treated with aripiprazole.

The subchronic antidopaminergic interventions in our study provoked a range of subjective and objective psychopathological impairments, which we have reported in detail previously.[@b57-ndt-14-1125],[@b58-ndt-14-1125] Our regression analyses showed these impairments were in some manner "synchronized" with posttreatment pHVA levels, consistent with a fundamental relationship with dopaminergic turnover in brain, despite the imperfect representation between pHVA and central dopamine. Friedhoff[@b84-ndt-14-1125] suggested that there might be a dopamine-dependent restorative system responsible for the maintenance of mental stability, whereby dopaminergic activity is normally regulated in the face of biological or psychological stressors. We suppose that present antidopaminergic interventions may have challenged this restorative system, unmasking an inherent association between pHVA levels with objective and subjective psychopathological impairments in healthy individuals.

Associations between pHVA and several mental domains have already been reported in different psychiatric diseases. A large body of clinical research has linked altered pHVA levels with psychotic states,[@b28-ndt-14-1125] symptom severity,[@b85-ndt-14-1125],[@b86-ndt-14-1125] negative symptoms, and anhedonia,[@b87-ndt-14-1125],[@b88-ndt-14-1125] as well as the occurrence of relapse of psychotic symptoms[@b89-ndt-14-1125] in schizophrenia. Furthermore, correlations between pHVA concentrations and psychotic symptoms have also been observed in delirium[@b90-ndt-14-1125] and Alzheimer's disease.[@b91-ndt-14-1125]

In our study, higher pHVA levels upon medication were associated with lower general well-being and self-assessed ability to concentrate in healthy volunteers treated with antidopaminergic compounds. These findings supplement observations about negative subjective experiences during treatment with antipsychotics,[@b92-ndt-14-1125]--[@b95-ndt-14-1125] which are associated with higher D~2~-receptor occupancy[@b96-ndt-14-1125]--[@b99-ndt-14-1125] in schizophrenia patients. Further, in our study pHVA also correlated with some objective and subjective items related to cognition (PANSS cognitive and VAS ability to concentrate). In our previous report, we showed that the antidopaminergic interventions resulted in pronounced impairments in the domains of information-processing speed, attention, and learning.[@b58-ndt-14-1125] Others have reported significant correlations between pHVA and stress experienced during performance of arithmetic tasks.[@b30-ndt-14-1125] Overall, the present association between impaired well-being and generally assessed cognitive impairments after antidopaminergic intervention with increased pHVA levels presents a mechanism for iatrogenic effects of off-label use of this class of compounds.

We now extend our earlier presentation of antidopaminergic effects on prolactin[@b54-ndt-14-1125] secretion to establish this as a surrogate marker for central effects. In the subgroup of healthy volunteers with \>50% increase in prolactin relative to baseline, we saw significantly greater general psycho-pathological impairments (PANSS score) and depressive symptoms (PANSS depressive), with a statistical trend toward lower self-assessment of well-being and concentration ability. This result concurs with a recent study performed in healthy volunteers, where higher baseline prolactin levels had a strong association with poorer cognition, well-being, and mood in healthy men.[@b100-ndt-14-1125] A similar association has been reported in late-pregnancy and postpartum women,[@b101-ndt-14-1125] and in relation to depression in women.[@b102-ndt-14-1125] An association between increased prolactin levels and impaired processing speed has been reported in early-psychosis patients,[@b103-ndt-14-1125] although declining prolactin levels after switching to aripiprazole were not associated with cognitive improvement in chronic patients.[@b104-ndt-14-1125]

A supplementary analysis revealed an association between the tolerability of haloperidol and the extent of prolactin increase. Those subjects experiencing side effects leading to dropout showed a significantly greater initial prolactin increase than those who tolerated haloperidol for 7 days. The association between prolactin increase (and subsequent hyperprolactinemia) and treatment with antipsychotic medication is a phenomenon replicated in numerous investigations since the 1970s.[@b105-ndt-14-1125] Treatments with risperidone, amisulpride, sulpiride, and first-generation antipsychotics are known to cause the highest rates of hyperprolactinemia.[@b106-ndt-14-1125] Further, multiple signs and symptoms have been described to emerge as a consequence of such pharmacologically induced hyperprolactinemia, ie, gynecomastia, galactorrhea, sexual dysfunction, infertility, oligomenorrhea, amenorrhoea,[@b107-ndt-14-1125] sexual dysfunction, decreased bone-mineral density (which may lead to increased risk of osteoporosis), and even increased risk of breast cancer and possibly prostate cancer.[@b108-ndt-14-1125] The present results thus indicate that iatrogenic hyperprolactinemia could serve as a predictor of objective psychopathological and cognitive impairments and general tolerability in the off-label use of antidopaminergic compounds.

Limitations and conclusion
==========================

As noted, only a third of pHVA and pMHPG originates from the human brain.[@b109-ndt-14-1125],[@b110-ndt-14-1125] Nevertheless, the use of pHVA as an index of central dopaminergic activity is supported by several studies in humans where treatment with a peripherally acting monoamine oxidase inhibitor did not ablate the relationship between cerebrospinal fluid HVA and residual pHVA.[@b76-ndt-14-1125],[@b21-ndt-14-1125],[@b111-ndt-14-1125] Although our use of the PANSS to assess changes in mental condition in healthy controls may seem controversial, it is justified by the present search for provoked psychopathological abnormalities after antidopaminergic interventions. Indeed, the PANSS proved sensitive to revealing such changes following rather low doses of the medications. Finally, the chosen antidopaminergic substances do not represent the commonly and most frequently off-label used antidopaminergic drugs. Indeed, our decision was primarily guided by the aim to examine the effects of the largely different antidopaminergic mechanisms of action represented by the selected substances. We concede the need in future studies to consider the use of quetiapine or risperidone, which are more commonly prescribed for off-label indications than the present medications.

Despite these caveats, we demonstrated that pharmacological perturbation of central dopaminergic transmission through antidopaminergic interventions in healthy volunteers provoked several objective and subjective mental impairments, which proved to correlate with increases in plasma levels of HVA and prolactin. Furthermore, our results suggest that early hyperprolactinemia could be predictive of tolerability of longer-term treatment, and thus spare patients risk from iatrogenic disease. Overall, the present results draw attention to the potent effects on dopamine-mediated processes evoked by antidopaminergic compounds, even when administered at the low doses typical of off-label indications.
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![Changes in monoamine metabolite concentrations after the 7-day medication period.\
**Notes:** (**A**) *P*=0.001; (**B**) *P*=0.009; (**C**) *P*=0.006.\
**Abbreviations:** HVA, homovanillic acid; MHPG, 3-methoxy-4-hydroxyphenylglycol; VMA, vanillylmandelic acid.](ndt-14-1125Fig1){#f1-ndt-14-1125}

![Prolactin (Prl) changes versus scales for third-party and subjective assessment.\
**Abbreviations:** PANSS, Positive and Negative Syndrome Scale; HRSD, Hamilton Rating Scale for Depression; BDI, Beck Depression Inventory; VAS, visual analogue scale.](ndt-14-1125Fig2){#f2-ndt-14-1125}

###### 

Demographic data concerning age, sex proportion, BMI, and education in the different groups

  ------------------------------------------------------------------------------------------------------------
  Treatment group   n    Age\          Female:male proportion   BMI        Education, years\   Estimated IQ\
                         (mean ± SD)                                       (mean ± SD)         (mean ± SD)
  ----------------- ---- ------------- ------------------------ ---------- ------------------- ---------------
  Aripiprazole      18   25.6±6.5      11:7                     24.4±4.5   15.9±2.1            123.8±18.4

  Haloperidol       18   27.2±6.1      8:10                     23.1±2.2   15.8±2.2            115.4±13.8

  Reserpine         18   27.7±7.6      8:10                     25.7±4.3   15.7±3.6            117.9±15.3

  Placebo           18   24.6±3.9      11:7                     23.2±2.5   16.8±2.6            114.3±14.7

  All               72   26.3±6.2      38:34                    24.1±3.6   16.0±2.7            117.9±15.8
  ------------------------------------------------------------------------------------------------------------

**Note:** For intelligence estimation, the German language multiple-choice test of verbal crystallized premorbid intelligence (Lehrl et al, 1995[@b112-ndt-14-1125]) was used.

**Abbreviation:** BMI, body-mass index.

###### 

Concentrations of catecholamine metabolites (ng/mL) in plasma (p) and urine (u) (ng/day)

  Plasma                                                                                                                                         
  -------------- ---------- ------------- ------------- -------------- ------------------------------------------------------------------------- ----------------------------------------------------------
  Placebo        18         13.84±6.1     14.24±6       2.2±6.8        *F*~3,61~ =0.45, *P*=0.717                                                NS
  Aripiprazole   18         16.73±5.93    16.45±5.24    −1.7±11.6                                                                                
  Haloperidol    11         13.51±5.4     15.21±4.3     12.6±2.4                                                                                 
  Reserpine      18         15.7±13.4     18.5±7.7      17.8±41.4                                                                                
                                                                                                                                                 
                 **n**      **pHIAA**     **pHIAA**     **Δ% pHIAA**   **RM ANOVA, time** × **group**                                            **Post hoc**
                                                                                                                                                 
  Placebo        18         6.55±3.3      7.27±3.7      10.1±12.1      *F*~3,61~=1.5, *P*=0.217                                                  NS
  Aripiprazole   18         8.26±4.67     7.53±3.77     −8.8±19.3                                                                                
  Haloperidol    11         5.05±1.5      5.71±2.6      12.9±1.9                                                                                 
  Reserpine      16         7.2±4.2       5.5±2.9       −23.6±3.3                                                                                
                                                                                                                                                 
                 **n**      **pMHPG**     **pMHPG**     **Δ% pMHPG**   **RM ANOVA, time** × **group**                                            **Post hoc**
                                                                                                                                                 
  Placebo        18         5.66±2.23     5.55±2.11     −1.5±2.2       *F*~3,59~=5.95, *P*=0.001[\*\*](#tfn4-ndt-14-1125){ref-type="table-fn"}   NS
  Aripiprazole   16         4.98±2.86     5.58±2.56     12.1±10.5                                                                                NS
  Haloperidol    11         6.75±3.9      6.14±3.5      −9.1±8.2                                                                                 NS
  Reserpine      18         4.06±2.14     6.3±2.9       55.2±35.5                                                                                *P*=0.001[\*\*](#tfn4-ndt-14-1125){ref-type="table-fn"}
                                                                                                                                                 
  **Urine**                                                                                                                                      
                                                                                                                                                 
                 **N**      **Day 1**     **Day 8**     **Δ% uHVA**    **RM ANOVA, time** × **group**                                            **Post hoc**
  **uHVA**       **uHVA**                                                                                                                        
                                                                                                                                                 
  Placebo        18         29.07±8.5     25.8±9.7      −11.2±5.3      *F*~3,61~=3.82, *P*=0.014[\*](#tfn3-ndt-14-1125){ref-type="table-fn"}     NS
  Aripiprazole   18         24.67±13.45   28.14±11.7    14.1±13                                                                                  NS
  Haloperidol    11         30.9±10.4     32.16±10      4.1±3.3                                                                                  NS
  Reserpine      18         24.3±9.2      37.98±13.73   56.3±40.4                                                                                *P*\<0.001[\*\*](#tfn4-ndt-14-1125){ref-type="table-fn"}
                                                                                                                                                 
                 **N**      **uHIAA**     **uHIAA**     **Δ% uHIAA**   **RM ANOVA, time** × **group**                                            **Post hoc**
                                                                                                                                                 
  Placebo        18         26.0±9.7      23.9±8.9      −8.1±7.2       *F*~3,61~=0.69, *P*=0.564                                                 NS
  Aripiprazole   18         22.29±12.6    23.27±8.5     4.4±3.1                                                                                  
  Haloperidol    11         29.0±15.8     21.45±6.9     −26.1±19.8                                                                               
  Reserpine      18         24.48±12.5    20.33±8.9     16.9±11.3                                                                                
                                                                                                                                                 
                 **N**      **uVMA**      **uVMA**      **Δ% uVMA**    **RM ANOVA, time** × **group**                                            **Post hoc**
                                                                                                                                                 
  Placebo        18         20.2±6.8      19.4±8.1      −4.1±2.1       *F*~3,61~=4.59, *P*=0.006[\*\*](#tfn4-ndt-14-1125){ref-type="table-fn"}   NS
  Aripiprazole   18         19.85±7.7     20.1±10.3     1.3±2.5                                                                                  NS
  Haloperidol    11         23.4±8.4      21.1±6.6      −9.8±7.6                                                                                 NS
  Reserpine      18         16.6±7.4      25.5±11.5     53.6±42.5                                                                                *P*=0.006[\*\*](#tfn4-ndt-14-1125){ref-type="table-fn"}

**Notes:**

*P*\<0.05;

*P*\<0.01. Before (day 1) and after the 7-day antidopaminergic intervention (day 8) in the four groups, outlined as means ± SD. The mean extent of concentration change after the medication period relative to day 1 is outlined as Δ% (\[{concentration measured on day 8 -- concentration measured on day 1}/concentration measured on day 1\] ×100).

**Abbreviations:** HVA, homovanillic acid; RM ANOVA, repeated-measures analysis of variance; HIAA, hydroxyindoleacetic acid; MHPG, 3-methoxy-4-hydroxyphenylglycol; VMA, vanillylmandelic acid.

###### 

Correlations among catecholamine metabolites in plasma and urine, scales for third-party assessment, and subjective assessment of some aspects of the mental condition

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                               HVA\                                                       5-HIAA\                                                  MHPG\      HVA\                                                5-HIAA\    VMA\
                               (plasma)                                                   (plasma)                                                 (plasma)   (urine)                                             (plasma)   (urine)
  ---------------------------- ---------------------------------------------------------- -------------------------------------------------------- ---------- --------------------------------------------------- ---------- ---------
  PANNS total                                                                                                                                                                                                                

   *r*                         0.51[\*\*](#tfn7-ndt-14-1125){ref-type="table-fn"}         NS                                                       NS         NS                                                  NS         NS

   *P*                         \<0.001[\*\*,\#](#tfn8-ndt-14-1125){ref-type="table-fn"}                                                                                                                                      

   *R*^2^                      0.27                                                                                                                                                                                          

   BC~a~ 95% CI                0.25--0.70                                                                                                                                                                                    

  PANSS cognitive                                                                                                                                                                                                            

   *r*                         0.49                                                       NS                                                       NS         0.30                                                NS         NS

   *P*                         0.001[\*\*,\#](#tfn8-ndt-14-1125){ref-type="table-fn"}                                                                         0.045[\*](#tfn6-ndt-14-1125){ref-type="table-fn"}              

   *R*^2^                      0.26                                                                                                                           0.09                                                           

   BC~a~ 95% CI                0.32--0.66                                                                                                                     −0.01 to 0.15                                                  

  PANSS depressive                                                                                                                                                                                                           

   *r*                         0.37                                                       NS                                                       NS         NS                                                  NS         NS

   *P*                         0.01[\*](#tfn6-ndt-14-1125){ref-type="table-fn"}                                                                                                                                              

   *R*^2^                      0.14                                                                                                                                                                                          

   BC~a~ 95% CI                0.02--0.63                                                                                                                                                                                    

  HRSD                                                                                                                                                                                                                       

   *r*                         0.39                                                       NS                                                       NS         NS                                                  NS         NS

   *P*                         0.007[\*](#tfn6-ndt-14-1125){ref-type="table-fn"}                                                                                                                                             

   *R*^2^                      0.15                                                                                                                                                                                          

   BC~a~ 95% CI                0.17--0.61                                                                                                                                                                                    

  BDI                                                                                                                                                                                                                        

   *r*                         0.313                                                      NS                                                       NS         NS                                                  NS         NS

   *P*                         0.03                                                                                                                                                                                          

   *R*^2^                      0.09                                                                                                                                                                                          

   BC~a~ 95% CI                0.004--0.57                                                                                                                                                                                   

  VAS ability to concentrate                                                                                                                                                                                                 

   *r*                         −0.48                                                      −0.36                                                    NS         NS                                                  NS         NS

   *P*                         0.001[\*\*,\#](#tfn8-ndt-14-1125){ref-type="table-fn"}     0.015[\*](#tfn6-ndt-14-1125){ref-type="table-fn"}                                                                                  

   *R*^2^                      0.23                                                                                                                                                                                          

   BC~a~ 95% CI                −0.65 to −0.31                                             −0.53 to −0.20                                                                                                                     

  VAS general well-being                                                                                                                                                                                                     

   *r*                         −0.44                                                      −0.46                                                    NS         NS                                                  NS         NS

   *P*                         0.002[\*\*,\#](#tfn8-ndt-14-1125){ref-type="table-fn"}     0.002[\*\*,\#](#tfn8-ndt-14-1125){ref-type="table-fn"}                                                                             

   *R*^2^                      0.19                                                       0.21                                                                                                                               

   BC~a~ 95% CI                −0.64 to 0.22                                              −0.62 to −0.3                                                                                                                      

  VAS fatigue                                                                                                                                                                                                                

   *r*                         0.37                                                       NS                                                       NS         NS                                                  NS         NS

   *P*                         0.011[\*](#tfn6-ndt-14-1125){ref-type="table-fn"}                                                                                                                                             

   *R*^2^                      0.14                                                                                                                                                                                          

   BC~a~ 95% CI                0.14--0.61                                                                                                                                                                                    

  VAS motivation                                                                                                                                                                                                             

   *r*                         NS                                                         NS                                                       NS         NS                                                  NS         NS

   *P*                                                                                                                                                                                                                       

   *R*^2^                                                                                                                                                                                                                    

   BC~a~ 95% CI                                                                                                                                                                                                              

  VAS drive                                                                                                                                                                                                                  

   *r*                         −0.34                                                      NS                                                       NS         NS                                                  NS         NS

   *P*                         0.021[\*](#tfn6-ndt-14-1125){ref-type="table-fn"}                                                                                                                                             

   *R*^2^                      0.12                                                                                                                                                                                          

   BC~a~ 95% CI                −0.62 to −0.05                                                                                                                                                                                
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:**

*P*\<0.05;

*P*\<0.01;

correlations remaining significant after Bonferroni correction (corrected significance level for ten scores and six metabolites *P*=0.003). Scales for third-party assessment (PANSS and HRSD) and assessment of mental condition (VAS and BDI) in the verum group measured on day 8 (24 hours after cessation of antidopaminergic intervention). PANSS subscales defined by the Lindenmayer et al model[@b52-ndt-14-1125] were analyzed separately.

**Abbreviations:** HVA, homovanillic acid; RM ANOVA, repeated-measures analysis of variance; HIAA, hydroxyindoleacetic acid; MHPG, 3-methoxy-4-hydroxyphenylglycol; VMA, vanillylmandelic acid; PANSS, Positive and Negative Syndrome Scale; HRSD, Hamilton Rating Scale for Depression; VAS, visual analogue scale; BDI, Beck Depression Inventory; BC~a~, bias corrected and accelerated; NS, not significant.

###### 

Prolactin changes vs scales for third-party and subjective assessment

  ------------------------------------------------------------------------------------------------------------------
                               Prolactin increase \<50%\   Prolactin increase \>50%\   One-way ANCOVA
                               (n=19)                      (n=35)                      
  ---------------------------- --------------------------- --------------------------- -----------------------------
  PANSS total                  41.2±9.2                    53.5±12.3                   *F*~1,51~=14.45, *P*\<0.001

  PANSS cognitive              7.4±2.9                     9.3±2.7                     *F*~1,51~=5.6, *P*=0.022

  PANSS depressive             5.4±0.8                     8.5±3.7                     *F*~1,51~=13.1, *P*=0.001

  HRSD                         3.6±3.9                     8.3±6.9                     *F*~1,51~=7, *P*=0.01

  BDI                          1.3±1.9                     4.3±4.9                     *F*~1,51~=7.4, *P*=0.009

  VAS ability to concentrate   64.1±25.9                   42.7±27.7                   *F*~1,51~=7.5, *P*=0.008

  VAS general well-being       64.8±26.8                   48.2±25.9                   *F*~1,51~=4.9, *P*=0.03

  VAS fatigue                  47.1±28.6                   56.7±24.6                   *F*~1,51~=1.6, *P*=0.217

  VAS motivation               64.4±23.4                   46.9±25.8                   *F*~1,51~=5.1, *P*=0.028

  VAS drive                    66.7±20.7                   44.3±26.2                   *F*~1,51~=10.1, *P*=0.003
  ------------------------------------------------------------------------------------------------------------------

**Abbreviations:** ANCOVA, analysis of covariance; PANSS, Positive and Negative Syndrome Scale; HRSD, Hamilton Rating Scale for Depression; BDI, Beck Depression Inventory; VAS, visual analogue scale.

###### 

Prolactin concentrations (mU/L) before and after 7-day medication period

  Treatment group      Baseline      After medication period   Difference
  -------------------- ------------- ------------------------- -------------
  Placebo              211.6±113.4   196.1±85.6                −15.4±66
  Aripiprazole         160.9±65      189.6±209.6               28.7±219.1
  Haloperidol          177.2±74.6    350.7±202.6               173.5±177.1
   Completers (n=11)   204.5±87.3    277.7±155.5               73.3±109.5
   Dropouts (n=7)      139.1±28.6    360.6±98.7                221.43±87.7
  Reserpine            149.6±80.2    540.3±280.8               390.7±263.7
